Jindan Yu
Overview
Dr. Jindan Yu is the Fray F. Marshall Chair in Biomedical Urologic Research at Emory University School of Medicine. She is a Professor and Vice Chair for Research in the Department of Urology, spearheading the discoveries of novel biomarkers and therapeutic approaches for aggressive prostate and genitourinary cancers. Dr. Yu also serves as the Scientific Director for Prostate and GU Cancer Research Program at Winship Cancer Institute of Emory University. She is a Professor in the Coulter Department of Biomedical Engineering at Georgia Tech-Emory and a Professor of Human Genetics, where she acts as the Faculty Lead for Cancer Genomics & Epigenomics at Emory.
Dr. Yu received her Bachelor of Medicine (equivalent to MD in US) at Peking University, Health Science Center in Beijing. She received her PhD in Biomedical Engineering with concentration on Biotechnology and Bioinformatics from the University of Michigan. Prior to joining the faculty at Emory in 2023, Dr. Yu held a position as a Professor in the Department of Medicine in the division of Hematology/Oncology and of Biochemistry and Molecular Genetics at the Northwestern University of Chicago, Illinois.
She has trained over 40 fellows and graduate students, served on over 30 PhD thesis committees and published nearly 90 articles in prestigious journals such as Nature Genetics, Molecular Cell, and the Journal of Clinical Investigation. Dr. Yu is the Fray F. Marshall Chair in Biomedical Urologic Research and Professor of Urology and Human Genetics. Dr. Yu serves as the Vice Chair for Research in the Department of Urology and Scientific Director for Prostate and GU Cancers Research at Winship based primarily at Winship Cancer Institute.
Academic Appointment
- Professor, Secondary Appointment, Department of Human Genetics, Emory University School of Medicine
- Vice Chair of Research, Department of Urology, Emory University School of Medicine
- Professor of Urology, Primary Appointment, Department of Urology, Emory University School of Medicine
Education
Degrees
- PhD from University of Michigan–Ann Arbor
- MS from University of Michigan–Ann Arbor
- MD from Peking University
Research
Publications
-
Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer.
Trends Endocrinol Metab
01/02/2025 Authors: Brea L; Yu J -
Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma.
Cancer Biol Ther Volume: 25 Page(s): 2364433
12/31/2024 Authors: Naranjo NM; Kennedy A; Testa A; Verrillo CE; Altieri AD; Kean R; Hooper DC; Yu J; Zhao J; Abinader O -
Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
Oncogene Volume: 43 Page(s): 484 - 494
02/01/2024 Authors: Ferrari MG; Jimenez-Uribe AP; Wang L; Hoeppner LH; Murugan P; Hahm E; Yu J; Kuzel TM; Gradilone SA; Mansini AP -
Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.
J Clin Invest Volume: 133
08/01/2023 Authors: Gritsina G; Fong K-W; Lu X; Lin Z; Xie W; Agarwal S; Lin D; Schiltz GE; Beltran H; Corey E -
Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target.
Res Sq
06/09/2023 Authors: Ferrari M; Wang L; Hoeppner L; Hahm E; Yu J; Kuzel T; Mansini A -
Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer.
Oncogene Volume: 42 Page(s): 2126 - 2138
06/01/2023 Authors: Lin Z; Agarwal S; Tan S; Shi H; Lu X; Tao Z; Dong X; Wu X; Zhao JC; Yu J -
Ferroptosis: the vulnerability within a cancer monster.
J Clin Invest Volume: 133
05/15/2023 Authors: Xie W; Agarwal S; Yu J -
CXCR7 as a novel therapeutic target for advanced prostate cancer.
Oncogene Volume: 42 Page(s): 785 - 792
03/01/2023 Authors: Gritsina G; Yu J -
PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing.
Mol Cell Volume: 82 Page(s): 4611 - 4626.e7
12/15/2022 Authors: Fong K-W; Zhao JC; Lu X; Kim J; Piunti A; Shilatifard A; Yu J -
FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.
Oncogene Volume: 41 Page(s): 4259 - 4270
09/01/2022 Authors: Wang X; Brea L; Lu X; Gritsina G; Park SH; Xie W; Zhao JC; Yu J